Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701558 | 1.00 | GNRHR (1.00) | GNRHRCYP3A4 | |
| SCHEMBL2701560 | 1.00 | GNRHR (1.00) | GNRHRCYP3A4 | |
| SCHEMBL4025314 | 0.88 | GNRHR (1.00) | GNRHRCYP3A4 | |
| SCHEMBL4025308 | 0.88 | GNRHR (1.00) | GNRHRCYP3A4 | |
| SCHEMBL4025310 | 0.88 | GNRHR (1.00) | GNRHRCYP3A4 | |
| SCHEMBL2701112 | 0.85 | GNRHR (0.75) | GNRHRCYP3A4 | |
| SCHEMBL2701116 | 0.85 | GNRHR (0.75) | GNRHRCYP3A4 | |
| SCHEMBL2701111 | 0.85 | GNRHR (0.75) | GNRHRCYP3A4 | |
| SCHEMBL2704231 | 0.84 | GNRHR (0.78) | GNRHRCYP3A4 | |
| SCHEMBL4998254 | 0.83 | GNRHR (0.84) | GNRHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644342-B1 | Arylpyrimidines useful for the treatment of sex hormone-related conditions such as endometriosis, prostate cancer and the like | NEUROCRINE BIOSCIENCES INC (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-1646389-B1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-7229995-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060122204-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| US-7015226-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050038056-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038056-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885CYP3A4 1434/4885 |
| US-20060122204-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GNRHR 1/4885CYP3A4 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.